Skip to content
Clinical trial Open access

Steady-State Pharmacokinetic Drug–Drug Interaction Study of Zastaprazan, a Novel Potassium-Competitive Acid Blocker, and Atorvastatin in Healthy Participants

Oct 2026 · Drug Design, Development and Therapy · Vol 20 · 0 citations · 17 references
Medicine

Abstract

Purpose Zastaprazan is a novel potassium-competitive acid blocker with CYP3A-mediated metabolism, whereas atorvastatin undergoes CYP3A4- and transporter-mediated disposition. Because these drugs may be co-administered and their net interaction cannot be inferred from shared metabolic pathways alone, this study evaluated their steady-state pharmacokinetic drug–drug interaction. Participants and Methods This open-label, fixed-sequence, three-period, multiple-dose study included healthy Korean men. Participants received atorvastatin 40 mg once daily, zastaprazan 20 mg once daily, and concomitant atorvastatin and zastaprazan, each for 5 consecutive days, under steady-state conditions. Plasma concentrations of zastaprazan, atorvastatin, and 2-hydroxyatorvastatin were measured, and geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated for Cmax,ss and AUCτ,ss. Results Twenty-four healthy Korean men received at least one dose of a study drug, and 22 were included in the pharmacokinetic analysis. Atorvastatin decreased zastaprazan Cmax,ss by approximately 26% (GMR, 0.740; 90% CI, 0.655–0.836), whereas AUCτ,ss was preserved (GMR, 1.054; 90% CI, 0.927–1.198). Zastaprazan did not meaningfully alter atorvastatin exposure (Cmax,ss GMR, 0.982; 90% CI, 0.806–1.195; AUCτ,ss GMR, 1.029; 90% CI, 0.944–1.122). The AUCτ,ss of 2-hydroxyatorvastatin showed a modest decrease (GMR, 0.940; 90% CI, 0.889–0.994) that remained within the predefined conventional reference range. Co-administration was generally well tolerated, with no serious adverse events or adverse event-related discontinuations. Conclusion Zastaprazan did not meaningfully alter atorvastatin Cmax,ss or AUCτ,ss under the studied conditions. Although atorvastatin reduced zastaprazan Cmax,ss, total exposure was preserved, a pattern consistent with altered absorption kinetics without establishing a specific mechanism. The pharmacodynamic significance of the lower zastaprazan Cmax,ss remains uncertain because intragastric pH was not measured. These pharmacokinetic findings do not suggest a need for atorvastatin dose adjustment under the studied conditions.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.